ANN ARBOR, MI—Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company with a market capitalization of $425 million and impressive revenue growth of 187% over the last twelve months, saw its Chief Financial Officer Benjamin Halladay recently sell a small number of shares in the company. According to a recent filing with the Securities and Exchange Commission, Halladay sold 9 shares of common stock on January 17 at a price of $2.265 per share, totaling approximately $20.
The transaction was made to satisfy tax obligations related to vested restricted stock units. For deeper insights into Esperion’s valuation and growth prospects, including exclusive ProTips and comprehensive financial analysis, visit InvestingPro, where you’ll find detailed research reports covering 1,400+ US stocks. Following this sale, Halladay retains ownership of 240,682 shares of Esperion Therapeutics.
In other recent news, Esperion Therapeutics has projected a significant increase in its operating expenses for the fiscal year ending December 31, 2025, with expected costs ranging between $215 million and $235 million. This forecast has raised concerns among investors about the company’s cost management and its impact on future profitability. Concurrently, Esperion has issued $100 million in 5.75% Convertible Senior Subordinated Notes due 2030 and secured a $150 million loan, with the aim of strengthening its financial position and extending the maturity of its debt.
Additionally, the company has entered into a licensing agreement with Neopharm Israel for the commercialization of its cardiovascular drugs NEXLETOL and NEXLIZET in Israel, Gaza, and the West Bank. This move aligns with Esperion’s broader international growth strategy.
Analyst coverage has been resumed by Goldman Sachs with a Neutral rating, while Cantor Fitzgerald initiated coverage with an Overweight rating. H.C. Wainwright maintained a Buy rating for Esperion, reflecting positive reception of the company’s strategic moves.
Lastly, Esperion’s third quarter of 2024 financial performance showed a 53% year-over-year increase in U.S. net product revenue, totaling $31.1 million, and a total revenue rise to $51.6 million, up from $34 million the previous year. These recent developments highlight Esperion’s ongoing efforts to expand its global reach and enhance its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.